Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
Description: Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in North America, the Pacific Rim, Europe, and internationally. It operates in two segments, Contract Research Services and Research Products. The Contract Research Services segment offers various services, including product characterization, method development, and validation; bioanalytical testing to measure drug and metabolite concentrations in complex biological matrices; and stability testing to establish and confirm product purity, potency, and shelf life. It also provides in vivo sampling services for the continuous monitoring of chemical changes in life; and pharmacokinetic and safety testing services, as well as provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services. The Research Products segment offers analytical produc
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.17||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-5.07%||Sales Growth - Q/Q||-2.04%||P/E||-9.35|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||31.27%||Operating Margin||-0.26%||Net Profit Margin||0.6%||Dividend Payout Ratio|
|Cash From Financing Activities||-750 K||Cash From Investing Activities||-230 K||Cash From Operating Activities||440 K||Gross Profit||1.8 M|
|Net Profit||150 K||Operating Profit||30 K||Total Assets||23.01 M||Total Current Assets||6.4 M|
|Total Current Liabilities||8.75 M||Total Debt||5.27 M||Total Liabilities||13.02 M||Total Revenue||5.73 M|
|High 52 week||2.1||Low 52 week||1.22||Last close||2.03||Last change||1.5%|
|RSI||56.25||Average true range||0.04||Beta||0.14||Volume||18.46 K|
|Simple moving average 20 days||1.6%||Simple moving average 50 days||2.35%||Simple moving average 200 days||18.49%|
|Performance Week||-0.49%||Performance Month||3.05%||Performance Quart||-0.98%||Performance Half||40.97%|
|Performance Year||23.91%||Performance Year-to-date||59.84%||Volatility daily||1.41%||Volatility weekly||3.15%|
|Volatility monthly||6.45%||Volatility yearly||22.36%||Relative Volume||145.56%||Average Volume||13.47 K|
|New High||New Low|
2019-08-15 12:38:29 | What Kind Of Investor Owns Most Of Bioanalytical Systems, Inc. NASDAQ:BASI?
2019-08-14 08:33:00 | BASi Continues Revenue Growth in Third Quarter of Fiscal 2019
2019-05-21 08:53:00 | Researchers Generate Better Data with BASi’s Redesigned Raturn™
2019-05-15 08:33:00 | BASi Continues Revenue Growth in Second Quarter of Fiscal 2019
2019-03-08 13:07:42 | Does Bioanalytical Systems, Inc. NASDAQ:BASI Have A Volatile Share Price?
2019-02-21 09:23:00 | BASi Appoints Joe Flynn as Chief Commercial Officer
2019-02-14 08:03:00 | BASi Reports Revenue Growth in First Quarter of Fiscal 2019
2018-12-20 08:03:00 | BASi Continues Revenue Gains to Close Fiscal 2018
2018-11-16 11:12:23 | Can Bioanalytical Systems Inc NASDAQ:BASI Improve Its Returns?
2018-11-01 08:43:00 | BASi Names John E. Sagartz Chief Strategy Officer
2018-10-17 08:33:00 | BASi Breaks Ground on Expansion of GLP Toxicology Facility in Indiana
2018-08-14 08:33:00 | BASi Reports Third Quarter Results with Revenue Gains
2018-07-09 09:00:00 | BASi Announces Appointment of John E. Sagartz to Board of Directors
2018-06-27 10:43:45 | Does Bioanalytical Systems Inc’s NASDAQ:BASI PE Ratio Signal A Buying Opportunity?
2018-05-25 16:57:18 | With An ROE Of 6.16%, Has Bioanalytical Systems Inc’s NASDAQ:BASI Management Done Well?
2018-05-15 08:33:00 | BASi Reports Second Quarter Results
2018-02-14 15:59:17 | Why Bioanalytical Systems Inc’s NASDAQ:BASI CEO Salary Matters To You
2018-02-13 07:00:00 | BASi Reports First Quarter Results
2018-02-12 11:36:23 | All You Need To Know About Bioanalytical Systems Inc’s NASDAQ:BASI Risks
2018-01-02 13:59:12 | Is Bioanalytical Systems Inc NASDAQ:BASI A Buy At Its Current PE Ratio?
2017-12-19 08:35:00 | BASi Continues Profitability Improvement to Close Out Fiscal 2017
2017-12-12 08:33:00 | BASi Announces Enhanced Bioequivalence Capabilities
2017-11-21 09:59:08 | What Investors Should Know About Bioanalytical Systems Inc’s BASI Financial Strength
2017-11-13 08:33:00 | Steady Growth Spurs Plans for BASi Expansion of GLP Toxicology Facility in Indiana